{"id":481006,"date":"2021-04-23T07:03:26","date_gmt":"2021-04-23T11:03:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/"},"modified":"2021-04-23T07:03:26","modified_gmt":"2021-04-23T11:03:26","slug":"castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/","title":{"rendered":"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population<\/b><\/p>\n<p class=\"bwalignc\"><i>The company also presented data on its genomic test for squamous cell carcinoma, DecisionDx-SCC<\/i><\/p>\n<p>FRIENDSWOOD, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCastle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, will present data at the American Academy of Dermatology\u2019s Virtual Meeting Experience, being held April 23 \u2013 25, 2021. The Company has two poster presentations highlighting its DecisionDx\u00ae-Melanoma and DecisionDx\u00ae-SCC genomic tests.\n<\/p>\n<p>\nData presentation information is as follows:\n<\/p>\n<p><b>DecisionDx<\/b>\u00ae<b>-Melanoma:<\/b><\/p>\n<p>\nThe poster is entitled, \u201cRisk stratification of patients with stage I cutaneous melanoma (CM) using 31-gene expression profiling (GEP).\u201d\n<\/p>\n<p>\nDecisionDx-Melanoma is Castle\u2019s 31-gene expression profile test that uses an individual patient\u2019s tumor biology to predict risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node (SLN) positivity, independent of traditional staging factors.\n<\/p>\n<p><i>Study methods and findings:<\/i><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nData were analyzed from 852 patients diagnosed with Stage I cutaneous melanoma according to the American Joint Committee on Cancer staging guidelines and a median follow-up of 3.8 years, who also had DecisionDx-Melanoma test results. Kaplan-Meier and Cox regression analyses were used to assess recurrence-free survival (RFS). Prognostic accuracy was assessed by comparing outcomes for Class 1A to outcomes for Class 2B.\n<\/li>\n<li>\nThe study demonstrated that along with staging factors (Breslow thickness and ulceration), a DecisionDx-Melanoma Class 2B (highest risk) result was a significant, independent predictor of recurrence in the stage I population.<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nA Class 2B DecisionDx-Melanoma result among these patients was associated with a recurrence rate of 20.4%, compared to the overall stage I population\u2019s recurrence risk of 4.6%.\n<\/li>\n<li>\nAmong all stage I melanoma patients, those with a Class 2B DecisionDx-Melanoma result had seven times the odds of experiencing a recurrence than patients with a Class 1A result.\n<\/li>\n<li>\nIn the subgroup of patients with a confirmed negative sentinel lymph node biopsy, those with a Class 2B DecisionDx-Melanoma result had five times the odds of experiencing a recurrence than patients with a Class 1A result.\n<\/li>\n<\/ul>\n<\/li>\n<li>\nAlthough the stage I population has a low aggregate risk of recurrence, the study demonstrated that DecisionDx-Melanoma identified patients within that population who may experience recurrence and benefit from increased management intensity.\n<\/li>\n<\/ul>\n<p><b>DecisionDx\u00ae-SCC:<\/b><\/p>\n<p>\nThe poster is entitled, \u201cProspective adjuvant therapy trial design using a prognostic 40-gene expression profile (40-GEP) test for high-risk cutaneous squamous cell carcinoma (cSCC) and BWH staging-based risk assessment.\u201d\n<\/p>\n<p>\nDecisionDx-SCC is Castle\u2019s prognostic 40-gene expression profile test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC) designed to use a patient\u2019s tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.\n<\/p>\n<p><i>Study methods and findings:<\/i><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThis analysis evaluated the impact of DecisionDx-SCC\u2019s risk stratification as enrollment criteria into trial design involving adjuvant therapy for SCC.\n<\/li>\n<li>\nUsing data from 420 validation cases, Brigham and Women\u2019s Hospital (BWH) T2a-T3 stage SCC patients with or without DecisionDx-SCC results of Class 2A\/B (high risk) or 2B (highest risk) were used for two-arm sample size calculations.\n<\/li>\n<li>\nMetastasis rates for cases with BWH T2a-T3 tumors were 20% without DecisionDx-SCC results and 27% or 57% when selecting for cases with Class 2A\/B or 2B results, respectively.\n<\/li>\n<li>\nIn the absence of DecisionDx-SCC results, 1,234 T2a-T3 patients would be required for randomization in a trial to provide 80% power to detect a hazard ratio of 0.7 with at least three years of follow-up (alpha=0.05), correlating with studies using the addition of radiation to surgery. However, sample size could be reduced to 915 (26% reduction) or 432 (65% reduction) patients by focusing enrollment on T2a-T3 patients with a DecisionDx-SCC Class 2A\/B or 2B result, respectively.\n<\/li>\n<li>\nUse of DecisionDx-SCC could be applied to improve trial inclusion criteria as it has demonstrated additive value for patient stratification in other risk assessment methods such as AJCC staging, NCCN risk groups, and individual risk factors.\n<\/li>\n<li>\nOverall, the study demonstrated that incorporation of DecisionDx-SCC testing into trial design to identify patients who are at the highest risk for metastasis could facilitate selection of those who are most appropriate for adjuvant therapy (e.g., Class 2B patients), expedite time to trial completion and optimize healthcare costs.\n<\/li>\n<\/ul>\n<p><b>About DecisionDx-Melanoma<\/b><\/p>\n<p>\nDecisionDx\u00ae-Melanoma is a gene expression profile test that uses an individual patient\u2019s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors, and has been studied in more than 5,700 patient samples. Using tissue from the primary melanoma, the test measures the expression of 31 genes. The test has been validated in four archival risk of recurrence studies of 901 patients and six prospective risk of recurrence studies including more than 1,600 patients. To predict likelihood of sentinel lymph node positivity, the Company utilizes its proprietary algorithm, i31-GEP, to produce an integrated test result. i31-GEP is an artificial intelligence-based neural network algorithm (independently validated in a cohort of 1,674 prospective, consecutively tested patients with T1-T4 cutaneous melanoma) that integrates the DecisionDx-Melanoma test result with the patient\u2019s traditional clinicopathologic features. Impact on patient management plans for one of every two patients tested has been demonstrated in four multicenter and single-center studies including more than 560 patients. The consistent performance and accuracy demonstrated in these studies provides confidence in disease management plans that incorporate DecisionDx-Melanoma test results. Through December 31, 2020, DecisionDx-Melanoma has been ordered more than 68,920 times for use in patients with cutaneous melanoma.\n<\/p>\n<p>\nMore information about the test and disease can be found at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.CastleTestInfo.com&amp;esheet=52417031&amp;newsitemid=20210423005129&amp;lan=en-US&amp;anchor=www.CastleTestInfo.com&amp;index=1&amp;md5=b48def632ef93005205f1e0bd4596c46\">www.CastleTestInfo.com<\/a>.\n<\/p>\n<p><b>About DecisionDx-SCC<\/b><\/p>\n<p>\nDecisionDx-SCC is a 40-gene expression profile test that uses an individual patient\u2019s tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors. The test result, in which patients are stratified into a Class 1, 2A or 2B risk category, predicts individual metastatic risk to inform risk-appropriate management.\n<\/p>\n<p>\nPeer-reviewed publications have demonstrated that DecisionDx-SCC is an independent predictor of metastatic risk and that integrating DecisionDx-SCC with current prognostic methods can add positive predictive value to clinician decisions regarding staging and management.\n<\/p>\n<p>\nMore information about the test and disease can be found at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.CastleTestInfo.com&amp;esheet=52417031&amp;newsitemid=20210423005129&amp;lan=en-US&amp;anchor=www.CastleTestInfo.com&amp;index=2&amp;md5=518628f3bdf45d3de4d9adb661b54396\">www.CastleTestInfo.com<\/a>.\n<\/p>\n<p><b>About Castle Biosciences<\/b><\/p>\n<p>\nCastle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx\u00ae-Melanoma, DecisionDx\u00ae-CM<i>Seq<\/i>), cutaneous squamous cell carcinoma (DecisionDx\u00ae-SCC), suspicious pigmented lesions (DecisionDx\u00ae DiffDx\u2122-Melanoma) and uveal melanoma (DecisionDx\u00ae-UM, DecisionDx\u00ae-PRAME and DecisionDx\u00ae-UM<i>Seq<\/i>). For more information about Castle\u2019s gene expression profile tests, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.CastleTestInfo.com&amp;esheet=52417031&amp;newsitemid=20210423005129&amp;lan=en-US&amp;anchor=www.CastleTestInfo.com&amp;index=3&amp;md5=2e0a48ebd4d460dac283d31eadf386de\">www.CastleTestInfo.com<\/a>. Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.CastleBiosciences.com&amp;esheet=52417031&amp;newsitemid=20210423005129&amp;lan=en-US&amp;anchor=www.CastleBiosciences.com&amp;index=4&amp;md5=fb32f4e14c9f98aa99451913d69a36cf\">www.CastleBiosciences.com<\/a>.\n<\/p>\n<p>\nDecisionDx-Melanoma, DecisionDx-CM<i>Seq<\/i>, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM<i>Seq<\/i> are trademarks of Castle Biosciences, Inc.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThe information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the \u201csafe harbor\u201d created by those sections. These forward-looking statements include, but are not limited to, statements concerning DecisionDx-Melanoma\u2019s ability to predict recurrence in the stage I population and identify patients within that population who may benefit from increased management intensity and statements concerning the ability of DecisionDx-SCC test results to provide additive value for patient stratification in other risk assessment methods such as AJCC staging, NCCN risk groups, and individual risk factors, identify patients who are at the highest risk for metastasis, facilitate selection of those who are most appropriate for adjuvant therapy (e.g., Class 2B patients), expedite time to trial completion and optimize healthcare costs. The words \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the effects of the COVID-19 pandemic on our business and our efforts to address its impact on our business, subsequent study results and findings that contradict earlier study results and findings, our products\u2019 ability to provide the aforementioned benefits to patients and the risks set forth in our Annual Report on Form 10-K for the year ended December 31, 2020, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210423005129r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210423005129\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210423005129\/en\/<\/a><\/span><\/p>\n<p><b>Investor and Media Contact:<br \/>\n<\/b><br \/>Camilla Zuckero<br \/>\n<br \/>832-835-5158<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:czuckero@castlebiosciences.com\">czuckero@castlebiosciences.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Texas<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Other Health Health Genetics Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population The company also presented data on its genomic test for squamous cell carcinoma, DecisionDx-SCC FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211; Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, will present data at the American Academy of Dermatology\u2019s Virtual Meeting Experience, being held April 23 \u2013 25, 2021. The Company has two poster presentations highlighting its DecisionDx\u00ae-Melanoma and DecisionDx\u00ae-SCC genomic tests. Data presentation information is as follows: DecisionDx\u00ae-Melanoma: The poster is entitled, \u201cRisk stratification of patients with stage I cutaneous melanoma (CM) using 31-gene expression profiling (GEP).\u201d DecisionDx-Melanoma is Castle\u2019s 31-gene expression profile test that &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-481006","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population The company also presented data on its genomic test for squamous cell carcinoma, DecisionDx-SCC FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211; Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, will present data at the American Academy of Dermatology\u2019s Virtual Meeting Experience, being held April 23 \u2013 25, 2021. The Company has two poster presentations highlighting its DecisionDx\u00ae-Melanoma and DecisionDx\u00ae-SCC genomic tests. Data presentation information is as follows: DecisionDx\u00ae-Melanoma: The poster is entitled, \u201cRisk stratification of patients with stage I cutaneous melanoma (CM) using 31-gene expression profiling (GEP).\u201d DecisionDx-Melanoma is Castle\u2019s 31-gene expression profile test that &hellip; Continue reading &quot;Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-23T11:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210423005129r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population\",\"datePublished\":\"2021-04-23T11:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\\\/\"},\"wordCount\":1564,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210423005129r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\\\/\",\"name\":\"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210423005129r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-04-23T11:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210423005129r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210423005129r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/","og_locale":"en_US","og_type":"article","og_title":"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population - Market Newsdesk","og_description":"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population The company also presented data on its genomic test for squamous cell carcinoma, DecisionDx-SCC FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211; Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, will present data at the American Academy of Dermatology\u2019s Virtual Meeting Experience, being held April 23 \u2013 25, 2021. The Company has two poster presentations highlighting its DecisionDx\u00ae-Melanoma and DecisionDx\u00ae-SCC genomic tests. Data presentation information is as follows: DecisionDx\u00ae-Melanoma: The poster is entitled, \u201cRisk stratification of patients with stage I cutaneous melanoma (CM) using 31-gene expression profiling (GEP).\u201d DecisionDx-Melanoma is Castle\u2019s 31-gene expression profile test that &hellip; Continue reading \"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-23T11:03:26+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210423005129r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population","datePublished":"2021-04-23T11:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/"},"wordCount":1564,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210423005129r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/","name":"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210423005129r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-04-23T11:03:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210423005129r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210423005129r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-presents-data-demonstrating-decisiondx-melanoma-as-significant-independent-predictor-of-recurrence-in-stage-i-cutaneous-melanoma-population\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/481006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=481006"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/481006\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=481006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=481006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=481006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}